GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
GAiT Director Susan Solomon introduces Nobel Laureate Prof Shinya Yamanaka at #NYSCF2019 annual conference this morning.
GAiT is at the annual NYSCF conference at Rockefeller University today and tomorrow. We are enjoying catching up with our American members.
GAiT will be attending the NYSCF annual conference in New York this Tuesday and Wednesday (22nd and 23rd October 2019). See program here
The NYSCF Conference - New York Stem Cell Foundation
The NYSCF Conference is the leading scientific meeting on translational stem cell research. It...
GAiT director Dr Jacqueline Barry talking about AMTP regulatory consequences of Brexit
Thanks to the organizers of Phacilitate Leaders Asia & World Stem Cell Summit - China for a good conference. We look forward to continue working with our Chinese members.
En route to Shanghai to speak about the iPSC Quality Round at Phacilitate Leaders Asia / World Stem Cell Summit - China http://www.phacilitate-leaders-asia.com
GAiT will be speaking in Shanghai this week about the induced Pluripotent Stem Cell Quality Round 2019 and how participation in such activity makes translation to the clinic more efficient. More at https://www.phacilitate-leaders-asia.com/
Prof Paul Fairchild (Oxford Uni) discusses immunological hurdles to stem cell therapies at UKRMP/Brit Pharma Soc stem cell safety meeting in Edinburgh Scotland today.